JADPRO Newsreels

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, discusses data from an analysis of prediabetic/obese patients with hormone receptor (HR)-postive, HER2-negative locally advanced/metastatic breast cancer. These patients received inavo...

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, reviews findings from a single-center retrospective analysis on how body composition measures—such as total fat, visceral fat, subcutaneous fat, skeletal muscle area, skeletal mus...

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, reviews new data from the INAVO120 study presented at the 2025 ASCO Annual Meeting—the final overall survival analysis and updated results on safety, efficacy, and toxicity. INAVO120 is a p...

Katie Sellers, MPAS, PA-C, discusses a phase II trial presented at the ASH Annual Meeting exploring de-escalated post-transplant cyclophosphamide (PTCy) with ruxolitinib for GVHD prophylaxis in older patients undergoing reduced intensity...

Katie Sellers, MPAS, PA-C, considers a post-hoc analysis focusing on transplant recipients aged ≥70 years in the BMT CTN 1703 trial (Abstract 1042). The study found that even in this older, frailer sub-population, post-transplant cycloph...

Katie Sellers, MPAS, PA-C, reviews findings from the Agave-201 study presented at the ASH Annual Meeting, which evaluated axatilimab, an anti-CSF1R monoclonal antibody, in chronic graft-versus-host disease (Abstract 98). Axatilimab showe...

Lindsey E. Kalhagen, MMS, PA-C, discusses a multinational, cross-sectional, online survey study (N = 155) that expanded on previous findings that 20 participants with myelofibrosis (MF) reported, in a series of elicitation interviews, su...

Lindsey E. Kalhagen, MMS, PA-C, discusses a single-center, retrospective, propensity-score matched study that compared clinical response, progression-free survival (PFS) and overall survival (OS) outcomes, and adverse events in 62 patien...

Lindsey E. Kalhagen, MMS, PA-C, discusses a multicenter, observational, retrospective study involving myelofibrosis patients with splenomegaly or symptoms and anemia who received momelotinib from March 2023 to July 2024. This study inclu...